The progress reports on the development of therapies of Duchenne muscular dystrophy
- PMID: 20128138
- PMCID: PMC2858951
The progress reports on the development of therapies of Duchenne muscular dystrophy
Abstract
The roots of the progress reports on the development of therapies for Duchenne muscular dystrophy (DMD) that since 2000 have been produced at Breitnau/Germany and distributed to the parents of DMD patients cover over 30 years of continual occupation with this disease. The beginning was marked by the development of an early detection programme for the genetic disposition for DMD in infant boys. The next step was the organisation of workshops on the management of DMD and the writing of progress reports on these and other relevant conferences. Getting acquainted with the ideas of the protagonists in the research field by holding interviews was a decisive prerequisite for this activity. This took place in tandem with the development of a new kind of multiplex "family letters" that attempted to answer frequently asked questions to many DMD families at the same time. When--with the beginning of the new millennium--the endeavours towards gene therapies for DMD started to boom all over the scientific world, progress reports designed to keep the families informed about research on DMD treatment were added to the family letters. These reports that give an account of the latest state of the research are written in a plain language that can be understood by laypersons. In the meantime the reports have adopted the character of reviews that are updated annually. They are written in English and German and translated into Spanish and many other languages.
Similar articles
-
Screening for Duchenne muscular dystrophy in Germany, 1977-2011: A personal story.Muscle Nerve. 2018 Feb;57(2):185-188. doi: 10.1002/mus.25979. Epub 2017 Nov 2. Muscle Nerve. 2018. PMID: 28981144
-
Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.JAMA Neurol. 2016 Jan;73(1):111-6. doi: 10.1001/jamaneurol.2015.3537. JAMA Neurol. 2016. PMID: 26594870 Review.
-
Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy.BioDrugs. 2021 Jul;35(4):389-399. doi: 10.1007/s40259-021-00486-7. Epub 2021 Jun 7. BioDrugs. 2021. PMID: 34097287 Review.
-
Duchenne expert physician perspectives on Duchenne newborn screening and early Duchenne care.Am J Med Genet C Semin Med Genet. 2022 Jun;190(2):162-168. doi: 10.1002/ajmg.c.31993. Epub 2022 Aug 5. Am J Med Genet C Semin Med Genet. 2022. PMID: 35932090 Free PMC article.
-
Comprehensive genetic analysis of 961 unrelated Duchenne Muscular Dystrophy patients: Focus on diagnosis, prevention and therapeutic possibilities.PLoS One. 2020 Jun 19;15(6):e0232654. doi: 10.1371/journal.pone.0232654. eCollection 2020. PLoS One. 2020. PMID: 32559196 Free PMC article.
References
-
- Zellweger H, Antonik A. Newborn screening for Duchenne muscular dystrophy. Pediatrics 1975;55:30-4. - PubMed
-
- Scheuerbrandt G, Lundin A, Lövgren T, et al. Screening for Duchenne muscular dystrophy: an improved screening test for creatine kinase and its application in an infant screening program. Muscle Nerve 1986;9:11-23. - PubMed
-
- Van Ommen GJB, Scheuerbrandt G. Workshop report: neonatal screening for muscular dystrophy. Neuromuscul Disord 1993;3:231-9. - PubMed
-
- Scheuerbrandt G. First meeting of the Duchenne Parent Project in Europe: treatment of Duchenne muscular dystrophy. 7-8 November 1997, Rotterdam, the Netherlands. Neuromuscul Disord 1998;8:213-9. - PubMed
-
- Scheuerbrandt G. Parent Project Muscular Dystrophy annual conference. Cincinnati, Ohio - 13-16 July 2006. Acta Myologica 2006;25:77-97. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources